In the case of both anti-VISTA mAbs and anti-CTLA-4 mAbs, the fundamental challenges to drug development include widespread expression of the target proteins in non-tumor tissue, and subsequently, the inability of conventional antibodies to discriminate between target in the TME versus non-tumor tissue. This evidence concerns the gene CTLA4 and neoplasm.